MedPath

Fructose-induced Intestinal de Novo Lipogenesis

Completed
Conditions
Obesity
Registration Number
NCT01792089
Lead Sponsor
University of Lausanne
Brief Summary

8 healthy volunteers, 8 pre-bypass obese subjects, 8 subjects between 12-18 months post-bypass, and 8 subjects matched to the post-bypass patients will be studied in two sub-studies Sub-study 1) after ingestion of two or three different of the following test-meals: A)cream and whey protein B)cream, whey protein and fructose + 13C6 fructose C)test meal with cream, whey protein, fructose and glucose + 13C6 fructose Their intestinal de novo lipogenesis will be estimated by measuring 13C-palmitate on triglyceride-rich lipoprotein particles associated with apoB48 in blood Sub-study 2) after ingestion of two or three different of the following test-meals: A)cream labelled with 13C6 palmitic acid and whey protein B))cream labelled with 13C6 palmitic acid, whey protein, fructose and glucose

Their intestinal de novo lipogenesis will be estimated by measuring 13C-palmitate on triglyceride-rich lipoprotein particles associated with apoB48 in blood in sub-study 1

Their exogenous lipid absorption kinetics will be assessed by measuring 13C palmitate on triglyceride-rich lipoprotein particles associated with apoB48 in sub-study 2

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
24
Inclusion Criteria
  • age 18-50 years
  • sex male or female
  • less than 2 kg body weight change over the past 3 months subjects
Exclusion Criteria
  • antidiabetic and hypolipemic drugs
  • alcohol consumption >20g/day
  • severe eating disorders
  • severe psychological problems
  • vegetarian diet or other specific diet
  • consumption of illicit substances
  • pregnancy
  • weight gain or weight loss > 1 kg in the last 3 months

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Intestinal de novo lipogenesis (sub-study 1)0-8-hour post-prandial

Measurement of total TG and 13C palmitate in chylomicrons: The sf \>20 fraction of post-prandial blood samples will be prepared, and non-chylomicrons, apoB100-containing lipoprotein will be removes by immuno-affinity chromatography using a specific anti-apoB100 antibody

Postprandial exogenous, labelled palmitate concentration (sub-study 2)0-8-hour post-prandial

Measurement of total TG and 13C palmitate in chylomicrons of sf \>20 fraction of post-prandial blood samples will be prepared,

Secondary Outcome Measures
NameTimeMethod
post-prandial triglyceride profile (sub-studies 1 and 20-8 hour post-prandial

Triglyceride will be measured in the chylomicron, VLDL, LDL and HDL fractions of post-prandial blood samples

Trial Locations

Locations (1)

Centre Hospitalier Universitaire Vaudois

🇨🇭

Lausanne, VD, Switzerland

Centre Hospitalier Universitaire Vaudois
🇨🇭Lausanne, VD, Switzerland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.